Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiviral vaccines].

M Girard1

  • 1Centre Européen de Recherche en Immunologie et Virologie, Lyon, France. mgirard@ens-bma.cnrs.fr

Medecine Tropicale : Revue Du Corps De Sante Colonial
|July 21, 2000
PubMed
Summary
This summary is machine-generated.

Modern vaccine development utilizes genetic engineering for subunit and live recombinant vaccines, alongside novel DNA and synthetic approaches. Challenges remain in creating effective vaccines for complex diseases like Hepatitis C and HIV.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete nucleotide sequence of the genomic RNA of a French isolate of Pepino mosaic virus (PepMV). Brief report.

Archives of virology·2002
Same author

The influence of long emersion on biota, ammonium fluxes and nitrification in intertidal sediments of Marennes-Oléron Bay, France.

Marine environmental research·2002
Same author

Inositol hexakisphosphate-mediated regulation of glutamate receptors in rat brain sections.

Hippocampus·2002
Same author

Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10.

Human molecular genetics·2001
Same author

DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.

Developments in biologicals·2001
Same author

On the evolutionary conservation of the cell death pathway: mitochondrial release of an apoptosis-inducing factor during Dictyostelium discoideum cell death.

Molecular biology of the cell·2001
Same journal

[Physiopathology of chronic arthritis following chikungunya infection in man].

Medecine tropicale : revue du Corps de sante colonial·2012
Same journal

[Judicial or administrative settlement of medical malpractice claims. Update on medical liability].

Medecine tropicale : revue du Corps de sante colonial·2012
Same journal

[Chikungunya epidemic in 2005-2006: questions from occupational health professionals].

Medecine tropicale : revue du Corps de sante colonial·2012
Same journal

[Administrative issues linked to health insurance coverage of chronic post-chikungunya rheumatism].

Medecine tropicale : revue du Corps de sante colonial·2012
Same journal

[Coverage of the chikungunya epidemic on Reunion Island in 2006 by the French healthcare system].

Medecine tropicale : revue du Corps de sante colonial·2012
Same journal

[Five-year outcome of mother-to-child transmission of chikungunya virus].

Medecine tropicale : revue du Corps de sante colonial·2012
See all related articles

Area of Science:

  • Vaccinology
  • Immunology
  • Biotechnology

Context:

  • Traditional vaccines (live, attenuated, inactivated) have controlled diseases like smallpox and polio.
  • Genetic engineering has introduced subunit and live recombinant vaccines.
  • New vaccine platforms include DNA vaccines and synthetic vaccines like lipopeptides.

Purpose:

  • To review advancements in vaccine technology beyond traditional methods.
  • To highlight the role of genetic engineering and novel platforms in vaccinology.
  • To identify current challenges in vaccine development.

Summary:

  • Subunit vaccines use purified antigens produced via genetic engineering.
  • Live recombinant vaccines employ attenuated viral or bacterial vectors (e.g., poxviruses).

Related Experiment Videos

  • DNA vaccines and synthetic lipopeptides are emerging platforms, with DNA vaccines showing promise in rodents but requiring human trials.
  • Oral and nasal vaccine delivery methods are under development.
  • Developing vaccines for Hepatitis C and HIV remains a significant scientific hurdle due to disease complexity.

    • Impact:

    • Advances in vaccine technology offer new strategies for disease prevention.
    • Novel platforms like DNA and synthetic vaccines hold potential for future immunization.
    • Overcoming challenges in complex diseases will expand the scope of vaccine efficacy.